Home/Pipeline/Lasvic (Lascufloxacin)

Lasvic (Lascufloxacin)

Bacterial Infections

MarketedActive

Key Facts

Indication

Bacterial Infections

Phase

Marketed

Status

Active

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Infectious Disease Pain

Other Bacterial Infections Drugs

Drug	Company	Phase	Status
Generic Portfolio Expansion - Anti-infectives	Alkaloid AD Skopje	Regulatory Submission	Active
Vibativ® (telavancin)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
Penicillin V API	Biotika	Commercial	Active
Sterile Injectable Antibiotics Portfolio	Steripharma	Approved	Active
Oral Antibiotic	Dawah Pharmaceuticals	ANDA Filed/Pre-approval	Active
XAB05/XAB06	Xenothera	Preclinical	Active
Antibacterial Program	Prosetta Biosciences	Preclinical	Active
Novel Antibiotic Class 1	ArrePath	Pre-clinical	Active
Novel Antibiotic Class 2	ArrePath	Pre-clinical	Active
Amoxicillin/AmoxiClav Generics	Puren Pharmaceuticals	Approved	Active
Ready-to-Use Antibiotics in Bags	Galenica Senese	Commercial	Active
Anti-infective Candidate(s)	China Resources Pharmaceutical Group	Phase II / Phase III	Active